Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price fell 2.4% during trading on Wednesday . The company traded as low as $9.36 and last traded at $9.39. 7,622 shares traded hands during trading, a decline of 99% from the average session volume of 828,979 shares. The stock had previously closed at $9.62.
Analyst Ratings Changes
Several analysts have recently commented on MESO shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Mesoblast in a research note on Thursday, August 29th. Piper Sandler upgraded Mesoblast from a "neutral" rating to an "overweight" rating and raised their price target for the company from $4.00 to $11.00 in a report on Tuesday, July 23rd. StockNews.com cut Mesoblast from a "hold" rating to a "sell" rating in a report on Wednesday, September 4th. Maxim Group raised shares of Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group upgraded shares of Mesoblast from a "hold" rating to a "buy" rating in a report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, Mesoblast currently has a consensus rating of "Moderate Buy" and an average price target of $11.50.
Get Our Latest Stock Analysis on MESO
Mesoblast Stock Performance
The stock has a fifty day moving average of $7.20 and a 200-day moving average of $7.04. The firm has a market capitalization of $1.07 billion, a P/E ratio of -8.40 and a beta of 3.47. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of Mesoblast by 50.1% in the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company's stock valued at $34,000 after buying an additional 1,663 shares during the last quarter. Perkins Coie Trust Co bought a new stake in shares of Mesoblast during the 2nd quarter worth about $68,000. Pine Valley Investments Ltd Liability Co acquired a new position in Mesoblast in the 2nd quarter valued at about $80,000. Rathbones Group PLC bought a new stake in shares of Mesoblast during the second quarter worth approximately $95,000. Finally, Chapin Davis Inc. lifted its holdings in Mesoblast by 50.0% during the 2nd quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock worth $102,000 after purchasing an additional 5,000 shares during the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
